X0306 4 2017-10-02 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001713712 Flynn Daniel Lee C/O DECIPHERA PHARMACEUTICALS, INC. 500 TOTTEN POND ROAD WALTHAM MA 02451 0 1 0 0 Chief Scientific Officer Common Stock 2017-10-02 4 C 0 147049 A 147049 I By Biochenomix, LLC Series A Preferred Stock 2017-10-02 4 C 0 22070 0.00 D Common Stock 124695 0 I By Biochenomix, LLC Series B-1 Preferred Stock 2017-10-02 4 C 0 1494 0.00 D Common Stock 8441 0 I By Biochenomix, LLC Series B-2 Preferred Stock 2017-10-02 4 C 0 1392 0.00 D Common Stock 7865 0 I By Biochenomix, LLC Series C Preferred Stock 2017-10-02 4 C 0 1071 0.00 D Common Stock 6048 0 I By Biochenomix, LLC Stock Option (Right to Buy) 1.89 2017-10-02 4 M 0 110727 D 2025-12-17 Common Stock 625607 0 D Stock Option (Right to Buy) 1.89 2017-10-02 4 M 0 625607 A 2025-12-17 Common Stock 625607 625607 D Stock Option (Right to Buy) 1.89 2017-10-02 4 M 0 24607 D 2025-12-17 Common Stock 139029 0 D Stock Option (Right to Buy) 1.89 2017-10-02 4 M 0 139029 A 2025-12-17 Common Stock 139029 139029 D Stock Option (Right to Buy) 3.95 2017-10-02 4 M 0 7000 D 2026-09-26 Common Stock 39550 0 D Stock Option (Right to Buy) 3.95 2017-10-02 4 M 0 39550 A 2026-09-26 Common Stock 39550 39550 D Stock Option (Right to Buy) 6.13 2017-10-02 4 M 0 26835 D 2027-06-03 Common Stock 151617 0 D Stock Option (Right to Buy) 6.13 2017-10-02 4 M 0 151617 A 2027-06-03 Common Stock 151617 151617 D Stock Option (Right to Buy) 29.71 2018-02-16 4 A 0 68500 0.00 A 2028-02-15 Common Stock 68500 68500 D Represents preferred stock of Deciphera Pharmaceuticals, LLC. Upon the closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into 5.65 shares of common stock of the Issuer. Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2018, subject to continued service through such dates. /s/ Jeffrey M. Held, Attorney-in-Fact 2018-09-20